Efficacy of GLP-1 Obesity Injections Reveals Varied Weight Loss Outcomes
Recent findings have raised questions about the effectiveness of GLP-1 obesity injections, such as Ozempic, Hugobee, and Mounjaro, which have gained popularity worldwide. Reports indicate that a significant number of individuals undergoing treatment may not experience the desired weight loss results. According to a report by The Guardian, clinical trials have shown that between 9% and one-third of participants did not lose at least 5% of their body weight, a stark contrast to earlier studies where most participants lost between 15% and 20% of their average weight.
For instance, a Canadian woman in her 50s, who has been prescribed various obesity treatments, reported minimal weight loss despite her efforts. She noted that while she managed to lose approximately 20 pounds through strict dietary control, she attributed this success to her own efforts rather than the medications. She described the struggle with cravings as overwhelming, likening it to withdrawal symptoms from a drug, although she clarified that this was not a medical comparison.
Similarly, another Canadian man, aged 57, shared his experience with a medication called Weego over a six-month period, during which he maintained a weight of around 242 pounds. Despite exercising regularly and making healthy dietary choices, he observed little change in his weight, although he did notice improvements in his blood sugar and cholesterol levels.
Experts in obesity treatment, such as Professor Alexander Miras from Ulster University, have pointed out that the lack of weight loss is not necessarily due to a lack of effort from patients. Instead, they suggest that the effectiveness of these drugs can vary significantly among individuals. Factors such as age, gender, and the presence of conditions like type 2 diabetes can impact how well these treatments work. For example, older adults and men tend to experience less weight loss compared to younger individuals and women.
Emerging research also indicates that genetic factors may play a role in how individuals respond to GLP-1 treatments. Certain genetic mutations related to brain receptors that interact with GLP-1 drugs could affect a person's response to these medications. Additionally, some individuals may develop "GLP-1 resistance," where the expected appetite suppression and blood sugar control are diminished, even at standard dosages.
Given these complexities, experts recommend that if GLP-1 treatments prove ineffective, patients should consider alternative obesity treatments or, if necessary, explore options for metabolic surgery. This nuanced understanding of obesity treatment underscores the importance of personalized approaches in managing weight and health outcomes.




